Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Intermediate endpoints are needed in early phase studies of men with metastatic castration-resistant prostate cancer (mCRPC) that can reliably predict success in phase 3 trials. Among men with measurable disease, objective response may provide information as to whether a treatment is likely to be successful.